180 related articles for article (PubMed ID: 26028049)
1. SUMOylation Modulates CFTR Biogenesis: Is the Pathway Druggable?
Ahner A; Frizzell RA
Curr Drug Targets; 2015; 16(9):965-75. PubMed ID: 26028049
[TBL] [Abstract][Full Text] [Related]
2. Cystic fibrosis transmembrane conductance regulator degradation: cross-talk between the ubiquitylation and SUMOylation pathways.
Ahner A; Gong X; Frizzell RA
FEBS J; 2013 Sep; 280(18):4430-8. PubMed ID: 23809253
[TBL] [Abstract][Full Text] [Related]
3. Non-native Conformers of Cystic Fibrosis Transmembrane Conductance Regulator NBD1 Are Recognized by Hsp27 and Conjugated to SUMO-2 for Degradation.
Gong X; Ahner A; Roldan A; Lukacs GL; Thibodeau PH; Frizzell RA
J Biol Chem; 2016 Jan; 291(4):2004-2017. PubMed ID: 26627832
[TBL] [Abstract][Full Text] [Related]
4. Divergent signaling via SUMO modification: potential for CFTR modulation.
Ahner A; Gong X; Frizzell RA
Am J Physiol Cell Physiol; 2016 Feb; 310(3):C175-80. PubMed ID: 26582473
[TBL] [Abstract][Full Text] [Related]
5. Targeting Molecular Chaperones for the Treatment of Cystic Fibrosis: Is It a Viable Approach?
Heard A; Thompson J; Carver J; Bakey M; Wang XR
Curr Drug Targets; 2015; 16(9):958-64. PubMed ID: 25981601
[TBL] [Abstract][Full Text] [Related]
6. Different SUMO paralogues determine the fate of wild-type and mutant CFTRs: biogenesis versus degradation.
Gong X; Liao Y; Ahner A; Larsen MB; Wang X; Bertrand CA; Frizzell RA
Mol Biol Cell; 2019 Jan; 30(1):4-16. PubMed ID: 30403549
[TBL] [Abstract][Full Text] [Related]
7. Small heat shock proteins target mutant cystic fibrosis transmembrane conductance regulator for degradation via a small ubiquitin-like modifier-dependent pathway.
Ahner A; Gong X; Schmidt BZ; Peters KW; Rabeh WM; Thibodeau PH; Lukacs GL; Frizzell RA
Mol Biol Cell; 2013 Jan; 24(2):74-84. PubMed ID: 23155000
[TBL] [Abstract][Full Text] [Related]
8. Small-Molecule Inhibitors Targeting Protein SUMOylation as Novel Anticancer Compounds.
Yang Y; Xia Z; Wang X; Zhao X; Sheng Z; Ye Y; He G; Zhou L; Zhu H; Xu N; Liang S
Mol Pharmacol; 2018 Aug; 94(2):885-894. PubMed ID: 29784649
[TBL] [Abstract][Full Text] [Related]
9. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy.
Hall JD; Wang H; Byrnes LJ; Shanker S; Wang K; Efremov IV; Chong PA; Forman-Kay JD; Aulabaugh AE
Protein Sci; 2016 Feb; 25(2):360-73. PubMed ID: 26444971
[TBL] [Abstract][Full Text] [Related]
10. Rescuing mutant CFTR: a multi-task approach to a better outcome in treating cystic fibrosis.
Amaral MD; Farinha CM
Curr Pharm Des; 2013; 19(19):3497-508. PubMed ID: 23331027
[TBL] [Abstract][Full Text] [Related]
11. Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Chung WJ; Goeckeler-Fried JL; Havasi V; Chiang A; Rowe SM; Plyler ZE; Hong JS; Mazur M; Piazza GA; Keeton AB; White EL; Rasmussen L; Weissman AM; Denny RA; Brodsky JL; Sorscher EJ
PLoS One; 2016; 11(10):e0163615. PubMed ID: 27732613
[TBL] [Abstract][Full Text] [Related]
12. Targeting ENaC as a Molecular Suspect in Cystic Fibrosis.
Bangel-Ruland N; Tomczak K; Weber WM
Curr Drug Targets; 2015; 16(9):951-7. PubMed ID: 25544019
[TBL] [Abstract][Full Text] [Related]
13. Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies.
Amaral MD
Curr Drug Targets; 2011 May; 12(5):683-93. PubMed ID: 21039334
[TBL] [Abstract][Full Text] [Related]
14. Targeting SUMO Signaling to Wrestle Cancer.
Kroonen JS; Vertegaal ACO
Trends Cancer; 2021 Jun; 7(6):496-510. PubMed ID: 33353838
[TBL] [Abstract][Full Text] [Related]
15. Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi.
Farinha CM; Matos P; Amaral MD
FEBS J; 2013 Sep; 280(18):4396-406. PubMed ID: 23773658
[TBL] [Abstract][Full Text] [Related]
16. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
Solomon GM; Marshall SG; Ramsey BW; Rowe SM
Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
[TBL] [Abstract][Full Text] [Related]
17. Cystic fibrosis: CFTR modulators and their mechanism of action.
Nieddu E
Curr Pharm Des; 2013; 19(19):3474-5. PubMed ID: 23331031
[No Abstract] [Full Text] [Related]
18. Molecular modelling approaches for cystic fibrosis transmembrane conductance regulator studies.
Odolczyk N; Zielenkiewicz P
Int J Biochem Cell Biol; 2014 Jul; 52():39-46. PubMed ID: 24735712
[TBL] [Abstract][Full Text] [Related]
19. CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis.
Verkman AS; Lukacs GL; Galietta LJ
Curr Pharm Des; 2006; 12(18):2235-47. PubMed ID: 16787252
[TBL] [Abstract][Full Text] [Related]
20. Developing Practical Therapeutic Strategies that Target Protein SUMOylation.
Cox OF; Huber PW
Curr Drug Targets; 2019; 20(9):960-969. PubMed ID: 30362419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
